ATE425186T1 - Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften - Google Patents

Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften

Info

Publication number
ATE425186T1
ATE425186T1 AT06703578T AT06703578T ATE425186T1 AT E425186 T1 ATE425186 T1 AT E425186T1 AT 06703578 T AT06703578 T AT 06703578T AT 06703578 T AT06703578 T AT 06703578T AT E425186 T1 ATE425186 T1 AT E425186T1
Authority
AT
Austria
Prior art keywords
regions
binding properties
immunoglobulin domains
molecule different
determining complementarity
Prior art date
Application number
AT06703578T
Other languages
English (en)
Inventor
Gordana Wozniak-Knopp
Florian Rueker
Gottfried Himmler
Original Assignee
F Star Biotech Forsch & Entw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Biotech Forsch & Entw filed Critical F Star Biotech Forsch & Entw
Application granted granted Critical
Publication of ATE425186T1 publication Critical patent/ATE425186T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
AT06703578T 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften ATE425186T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64114405P 2005-01-05 2005-01-05

Publications (1)

Publication Number Publication Date
ATE425186T1 true ATE425186T1 (de) 2009-03-15

Family

ID=36445146

Family Applications (4)

Application Number Title Priority Date Filing Date
AT06011173T ATE423140T1 (de) 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT06703578T ATE425186T1 (de) 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT08168439T ATE548386T1 (de) 2005-01-05 2006-01-05 Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT06121439T ATE414718T1 (de) 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06011173T ATE423140T1 (de) 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT08168439T ATE548386T1 (de) 2005-01-05 2006-01-05 Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
AT06121439T ATE414718T1 (de) 2005-01-05 2006-01-05 Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften

Country Status (23)

Country Link
US (8) US20090298195A1 (de)
EP (4) EP2028193B1 (de)
JP (3) JP4937138B2 (de)
KR (2) KR20130105885A (de)
CN (2) CN101098891B (de)
AT (4) ATE423140T1 (de)
AU (1) AU2006204459B2 (de)
BR (1) BRPI0606399A8 (de)
CA (1) CA2594356C (de)
CY (3) CY1108767T1 (de)
DE (3) DE602006003695D1 (de)
DK (4) DK1772465T3 (de)
EA (1) EA018897B1 (de)
ES (4) ES2321861T3 (de)
HR (3) HRP20090326T1 (de)
IL (1) IL184103A (de)
MX (1) MX2007008118A (de)
NZ (1) NZ555893A (de)
PL (3) PL1752471T3 (de)
PT (4) PT1772465E (de)
RS (3) RS50830B (de)
SI (3) SI1699826T1 (de)
WO (1) WO2006072620A1 (de)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3002651B2 (ja) 1997-06-18 2000-01-24 株式会社日立製作所 クレーンおよび振れ止め方法
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP1975178A1 (de) * 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transzytotischer modularer Antikörper
WO2008124858A2 (en) * 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
CA2685049A1 (en) 2007-05-24 2008-11-27 Avir Green Hills Biotechnology Research Development Trade Ag Antibodies useful for therapy and diagnosis of cancer
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
SG189769A1 (en) * 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
AU2014200215B2 (en) * 2008-01-31 2016-09-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
AU2009212747B2 (en) 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (de) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
BRPI0920749A8 (pt) 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
CA2747154C (en) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN101609096B (zh) * 2009-07-21 2012-11-07 上海师范大学 肺癌标志物检测免疫层析试纸的制备方法
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
US20130189247A1 (en) * 2010-02-12 2013-07-25 Research Corporation Technologies, Inc. Multimeric Proteins Comprising Immunoglobulin Constant Domains
EP2407487A1 (de) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispezifische modulare Antikörper
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP3029066B1 (de) 2010-07-29 2019-02-20 Xencor, Inc. Antikörper mit modifizierten isoelektrischen punkten
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2640750A1 (de) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
AU2012214274B2 (en) 2011-02-11 2017-02-02 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
RU2632647C2 (ru) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP2546268A1 (de) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalisierendes Immunglobulin
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2751386T3 (es) * 2011-12-21 2020-03-31 Amgen Inc Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
EP2802355B1 (de) * 2012-01-09 2018-09-05 CovX Technologies Ireland Limited Mutante antikörper und konjugation davon
CN102585000B (zh) * 2012-02-22 2013-05-29 尉军 一种肿瘤标志物cd25自身抗体及应用
EP2825557B1 (de) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Manipuliertes lösliches monomeres fc
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
MX2014014894A (es) * 2012-06-04 2015-02-20 Irm Llc Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
KR102308915B1 (ko) 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
CA2906674C (en) 2013-03-14 2023-01-10 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
EP3628685A1 (de) 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Menschliche fcrn-bindungsmodifizierte antikörper und verfahren zur verwendung
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ， インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
KR101800295B1 (ko) 2013-09-04 2017-12-20 엘지디스플레이 주식회사 위치감지방법, 위치감지장치, 안테나 장치 및 디스플레이 장치
GB201317622D0 (en) * 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
NZ758715A (en) 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CN105940107B (zh) * 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
SG11201605046YA (en) 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
CA2932364A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
EP3122779B1 (de) * 2014-03-24 2019-05-22 Cancer Research Technology Limited Modifizierte antikörper mit modifizierten igg2-domänen zum hervorrufen agonistischer oder antagonistischer eigenschaften und verwendung davon
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
TWI679259B (zh) 2014-08-11 2019-12-11 德商漢高智慧財產控股公司 光學透明的熱熔黏著劑及其用途
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
EP3234107B1 (de) 2014-12-19 2022-09-14 Immusoft Corporation B-zellen zur in-vivo-verabreichung von therapeutika
EP3237449A2 (de) 2014-12-22 2017-11-01 Xencor, Inc. Trispezifische antikörper
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
ES2979088T3 (es) 2015-03-05 2024-09-24 Fred Hutchinson Cancer Center Proteínas de fusión inmunomoduladoras y usos de las mismas
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
EP4140492A1 (de) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutische gepoolte blutapoptotische zellpräparate und verwendungen davon
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US20180355318A1 (en) 2015-04-29 2018-12-13 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
EP3670535A1 (de) 2015-08-03 2020-06-24 EngMab Sàrl Monoklonale antikörper gegen bcma
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
IL258189B2 (en) * 2015-10-05 2023-03-01 Fredax Ab Antibodies from humans against prostate-specific antigen (5I.10)
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
CN105664157A (zh) * 2016-03-11 2016-06-15 江苏亲合力病毒检测工程有限公司 一种抗巨细胞病毒人源化抗体药物
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
TW201742625A (zh) 2016-03-15 2017-12-16 阿斯特捷利康公司 組合療法
CA3020330A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions
EP4711465A2 (de) 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Zusammensetzungen und verfahren zur programmierung therapeutischer zellen unter verwendung gezielter nukleinsäurenanoträger
PT3461261T (pt) 2016-05-20 2025-07-31 Harpoon Therapeutics Inc Proteínas de ligação ao cd3 de fragmento variável de cadeia única
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR102306744B1 (ko) 2016-06-17 2021-09-28 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
EP3472207B1 (de) 2016-06-20 2021-01-20 F-Star Delta Limited An pd-l1 und lag-3 bindende bindemoleküle
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
EP3484516A4 (de) 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center Mehrere bispezifische bindungsdomänenkonstrukte mit unterschiedlicher epitopbindung zur behandlung von krebs
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP4529966A3 (de) 2016-08-29 2025-06-18 Fred Hutchinson Cancer Center Chelatbildende plattform zur abgabe von radionukliden
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018048812A1 (en) 2016-09-06 2018-03-15 The Regents Of The University Of California Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3520117B1 (de) 2016-09-29 2023-11-08 The Regents of The University of California Trennung von metallionen durch flüssig-flüssig-extraktion
EP3519034A4 (de) 2016-09-29 2021-02-17 The Regents of The University of California Chelatbildende moleküle
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3544997A4 (de) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. Prostataspezifisches membranantigenbindendes proteine
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
WO2018106993A1 (en) * 2016-12-09 2018-06-14 H. Lee Moffitt Cancer Center And Research Institute Inc. Tlr9-binding chimeric antigen receptors
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
EP3720963A4 (de) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit veränderter bindung der variablen antikörper-regionen cd3 und cd137
EP3723787A4 (de) 2017-12-14 2021-09-01 Bluebird Bio, Inc. Daric-interleukinrezeptoren
EP3728302A1 (de) 2017-12-19 2020-10-28 Xencor, Inc. Modifizierte il-2-fc-fusionsproteine
AU2018387741B2 (en) * 2017-12-19 2025-09-25 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3773911A2 (de) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
US20210284728A1 (en) * 2018-05-14 2021-09-16 Harpoon Therapeutics, Inc. Dual binding moiety
WO2019222283A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
CA3100712A1 (en) * 2018-05-17 2019-11-21 Immunome, Inc. Ch3 domain epitope tags
KR20210009421A (ko) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
US12344672B2 (en) 2018-07-12 2025-07-01 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
TW202017947A (zh) * 2018-08-22 2020-05-16 美商戴納立製藥公司 抗her2 多肽及其使用方法
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
EP3849565A4 (de) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center Verminderung der cd33-expression zum selektiven schutz von therapeutischen zellen
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20220054544A1 (en) * 2018-09-21 2022-02-24 Harpoon Therapeutics, Inc. Conditionally active receptors
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3856789A4 (de) 2018-09-28 2022-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit variabler region eines veränderten antikörpers
MX2021003765A (es) 2018-10-03 2021-07-15 Xencor Inc Proteínas il-12 de fusión a fc heterodimérico.
CN118356479A (zh) 2018-10-17 2024-07-19 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN113366479A (zh) 2018-12-14 2021-09-07 蓝鸟生物公司 二聚化剂调节的免疫受体复合物
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
JP7583411B2 (ja) 2019-04-10 2024-11-14 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
EP3966249A4 (de) 2019-05-08 2023-05-10 2seventy bio, Inc. Gegen cll-1 gerichtete immuntherapien
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
CN112898412A (zh) * 2019-12-03 2021-06-04 复旦大学 一种高稳定性类Fab抗体及其制备方法和应用
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
EP4082570B1 (de) 2019-12-27 2026-02-25 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4-antikörper und verwendung davon
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
IL295448A (en) 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP7773528B2 (ja) 2020-08-19 2025-11-19 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
WO2022044248A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
MX2023012376A (es) * 2021-04-19 2024-01-22 Janssen Biotech Inc Moléculas con variantes de la región constante de anticuerpo diseñadas genéticamente.
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
US20240226319A1 (en) 2021-05-25 2024-07-11 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
JP2024523034A (ja) 2021-06-18 2024-06-25 エフ． ホフマン－ラ ロシュ アーゲー 二重特異性抗ｃｃｌ２抗体
CN117545779B (zh) 2021-06-25 2025-04-04 中外制药株式会社 抗ctla-4抗体的用途
CN117616123B (zh) 2021-06-25 2024-11-08 中外制药株式会社 抗ctla-4抗体
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
EP4577306A1 (de) 2022-08-26 2025-07-02 Merck Patent GmbH Kombinationskrebsbehandlung mit einem anti-msln/cd137-antikörper und pd-1/pd-l1-inhibitor
CN119836301A (zh) 2022-08-26 2025-04-15 默克专利股份公司 包括抗msln/cd137抗体和化疗剂的癌症治疗
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2026038050A2 (en) 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038047A2 (en) 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038048A2 (en) 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584209T2 (de) 1984-03-01 1995-05-04 Univ Leland Stanford Junior T-zellenrezeptor, spezifisch für antigenpolypeptide und verwandte polynukleotide.
DE3588239T3 (de) * 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US5763192A (en) * 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3283041B2 (ja) 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
DE69318016D1 (de) 1992-05-08 1998-05-20 Creative Biomolecules Inc Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen
CA2145278C (en) * 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US6194166B1 (en) * 1993-05-24 2001-02-27 Takara Shuzo Co., Ltd. Gene regulating aureobasidin sensitivity
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US20020106370A1 (en) * 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6358709B1 (en) * 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6352842B1 (en) * 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6477506B1 (en) * 1998-02-23 2002-11-05 Sony Corporation Terminal apparatus, information service center, transmitting system, and transmitting method
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) * 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
JP2002534966A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド オリゴヌクレオチド媒介核酸組換え
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
AU3719500A (en) * 1999-03-05 2000-09-21 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
EP1189931B1 (de) 1999-07-02 2006-06-21 Genentech, Inc. An her2 bindende peptidverbindungen
MX340559B (es) 1999-12-06 2016-07-14 Board Of Trustees Of The Univ Of Illinois Proteinas de tcr de alta afinidad y metodos.
EP1118661A1 (de) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T-Zellrezeptor-Bibliotheken
JP2003274960A (ja) 2000-02-03 2003-09-30 Japan Science & Technology Corp 可溶性ｔ細胞受容体タンパク質およびその作成方法
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
AU2001243670A1 (en) 2000-03-20 2001-10-03 Maxygen, Inc. Method for generating recombinant dna molecules in complex mixtures
JP2003533187A (ja) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
WO2002006469A2 (en) 2000-07-18 2002-01-24 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
JP2002058479A (ja) 2000-08-14 2002-02-26 Canon Inc 構造認識アミノ酸配列の取得方法
JP2004526419A (ja) * 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
CA2428140A1 (en) * 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
WO2002088171A2 (en) * 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1281757A1 (de) 2001-07-31 2003-02-05 Direvo Biotech AG Methode zur Herstellung von Nukleinsäuren mit stochastisch kombinierten Abschnitten von Ausgangsnukleinsäuren
EP1421115B1 (de) 2001-08-31 2005-03-02 Avidex Limited Löslicher t zell rezeptor
DE60232672D1 (de) 2001-10-01 2009-07-30 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
WO2003034995A2 (en) 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
US20040043424A1 (en) * 2001-11-15 2004-03-04 Baughn Mariah R Immunoglobulin superfamily proteins
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
WO2003070190A2 (en) * 2002-02-19 2003-08-28 Syntherica Corporation Surrogate antibodies and methods of preparation and use thereof
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE475431T1 (de) 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US20040097711A1 (en) * 2002-03-12 2004-05-20 Henry Yue Immunoglobulin superfamily proteins
EP1394251A1 (de) 2002-08-23 2004-03-03 Direvo Biotech AG Verfahren zur selektiven Zufallsmutagenese von Polynukleotiden
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
JP2006523437A (ja) 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2005021595A1 (en) 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
CA2550551C (en) 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1756278B1 (de) 2004-05-19 2008-09-17 MediGene Ltd. Verfahren zur verbesserung von t-zellrezeptoren
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CN101103045B (zh) * 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
MX2007003910A (es) 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
EP1812574A2 (de) 2004-11-18 2007-08-01 Avidex Limited Lösliche bifunktionelle proteine
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2007808A4 (de) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc Bindungsproteine mit einem immunoglobulinband und fc-bereichen mit modifizierten fc-effektor-funktionen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
EP1975178A1 (de) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transzytotischer modularer Antikörper
US7514271B2 (en) 2007-03-30 2009-04-07 International Business Machines Corporation Method of forming high density planar magnetic domain wall memory
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
AU2009212747B2 (en) 2008-01-31 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
US20120094874A1 (en) 2009-07-09 2012-04-19 F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H Stabilized immunoglobulin constant domains
US20120010388A1 (en) 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (de) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispezifische modulare Antikörper
US20140087957A1 (en) 2012-09-25 2014-03-27 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療

Also Published As

Publication number Publication date
DE602006005200D1 (de) 2009-04-02
KR101404512B1 (ko) 2015-01-29
HRP20090087T3 (en) 2009-03-31
EP1752471B1 (de) 2008-11-19
US20190382470A1 (en) 2019-12-19
US20090298195A1 (en) 2009-12-03
JP2008526809A (ja) 2008-07-24
PT2028193E (pt) 2012-06-15
HRP20090228T1 (en) 2009-05-31
US20230340696A1 (en) 2023-10-26
CY1109143T1 (el) 2014-07-02
ATE414718T1 (de) 2008-12-15
DE602006005526D1 (de) 2009-04-23
US20120028839A1 (en) 2012-02-02
DE602006003695D1 (de) 2009-01-02
US11084868B2 (en) 2021-08-10
CN101098891B (zh) 2014-05-21
KR20070092242A (ko) 2007-09-12
AU2006204459B2 (en) 2012-11-01
JP2012131792A (ja) 2012-07-12
EA200701443A1 (ru) 2008-02-28
PT1699826E (pt) 2009-06-17
US20200079837A1 (en) 2020-03-12
ES2384039T3 (es) 2012-06-28
RS50752B (sr) 2010-08-31
DK1752471T3 (da) 2009-03-16
DK2028193T3 (da) 2012-07-02
EP2028193B1 (de) 2012-03-07
EP1752471A1 (de) 2007-02-14
AU2006204459A1 (en) 2006-07-13
CN103555733A (zh) 2014-02-05
US9856311B2 (en) 2018-01-02
CN101098891A (zh) 2008-01-02
EP2028193A1 (de) 2009-02-25
HRP20090326T1 (en) 2009-07-31
BRPI0606399A2 (pt) 2009-06-23
JP2014058564A (ja) 2014-04-03
DK1699826T3 (da) 2009-07-06
EP1772465B1 (de) 2009-02-18
EP1772465A1 (de) 2007-04-11
ES2323651T3 (es) 2009-07-22
CA2594356A1 (en) 2006-07-13
RS50830B (sr) 2010-08-31
JP4937138B2 (ja) 2012-05-23
IL184103A (en) 2010-11-30
ES2320374T3 (es) 2009-05-21
PL1772465T3 (pl) 2009-08-31
SI1699826T1 (sl) 2009-08-31
MX2007008118A (es) 2008-03-13
RS50785B (sr) 2010-08-31
US20120028303A1 (en) 2012-02-02
CY1108767T1 (el) 2014-04-09
US9045528B2 (en) 2015-06-02
CY1110895T1 (el) 2015-06-10
PT1752471E (pt) 2009-02-26
JP5483294B2 (ja) 2014-05-07
SI1772465T1 (sl) 2009-06-30
EA018897B1 (ru) 2013-11-29
DK1772465T3 (da) 2009-05-25
US11499249B2 (en) 2022-11-15
WO2006072620A1 (en) 2006-07-13
PL1699826T3 (pl) 2009-08-31
PT1772465E (pt) 2009-05-21
EP1699826A1 (de) 2006-09-13
EP1752471B9 (de) 2009-04-15
JP5717833B2 (ja) 2015-05-13
US10385118B2 (en) 2019-08-20
ATE548386T1 (de) 2012-03-15
US20110251375A1 (en) 2011-10-13
BRPI0606399A8 (pt) 2022-12-13
CA2594356C (en) 2018-07-17
NZ555893A (en) 2009-12-24
ATE423140T1 (de) 2009-03-15
KR20130105885A (ko) 2013-09-26
IL184103A0 (en) 2007-10-31
ES2321861T3 (es) 2009-06-12
SI1752471T1 (sl) 2009-04-30
EP1699826B1 (de) 2009-03-11
PL1752471T3 (pl) 2009-04-30
US20170204164A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
ATE414718T1 (de) Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
CY1120723T1 (el) Ανταγωνιστικα αντισωματα il-17
NO2017032I1 (no) bezlotoksumab
DE602004017726D1 (de) Pegylierte Single-domain-antikörper (dAb)
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
DK1771732T3 (da) Taxol-immunassay
ATE482980T1 (de) Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen
EA202190599A1 (ru) Анти-tigit антитела

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1699826

Country of ref document: EP